News Novartis/Amgen migraine drug shows promise Mid-stage data suggests drug reduces monthly migraine days.
News Novartis Breezhaler bests GSK's Seretide in COPD Ultibro showed consistent reductions in rate of all exacerbations, whether mild, moderate, or severe.
Views & Analysis Novartis committed to CAR-Ts - but doubts about commercial v... Novartis may have concerns about commercial prospects, says expert.
News Novartis move damages CAR-T confidence Swiss pharma axes gene therapy unit, causing investor angst.
News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
